Pages tagged "SBIR"
-
Orphagen Awarded SBIR Grant
Posted on News From Our Members by Danielle Hayes · August 28, 2015 9:29 PMJuly 1, 2015. Orphagen Pharmaceuticals announced today that the National Institutes of Health (NIH) National Cancer Institute (NCI) has awarded the company $224,954 under the Small Business Innovative Research (SBIR) program to identify small molecule antagonist ligands for an novel drug discovery target for cancer immunotherapy. Orphagen proposes to find drug-like molecules to a previously unexplored orphan drug target that normally suppresses the immune response.
“We believe there is an opportunity to identify small molecule ligands to this orphan drug target. The ligands will enhance T cell activation and thus stimulate anti-tumor responses by enhancing the ongoing immune surveillance that already occurs in cancer patients.” said Dr. Haiyan Tao, Scientist and Principal Investigator of the grant. The drug-like molecules identified from this project would create a powerful and potentially safer therapeutic tool to enhance clinical cancer immunotherapy and improve patient survival.
Orphagen is a first-mover in the identification of small molecule compounds to three orphan nuclear receptors. Support from the NIH is a critical part of the Company’s overall strategy to discover new classes of drugs and commercialize them through partnerships.
-
Crinetics Pharmaceuticals Awarded $1.5MM NIH Phase II SBIR Grant for PCOS Research
Posted on News From Our Members by Danielle Hayes · February 15, 2015 6:00 PMCrinetics Pharmaceuticals receives a $1.5MM Phase II SBIR grant to develop orally-available, small molecule kisspeptin receptor antagonists to treat polycystic ovary syndrome (PCOS) and other women’s health disorders.
Read more -
Arisan Therapeutics Receives $600,000 SBIR Award
Posted on News From Our Members by Danielle Hayes · May 01, 2014 11:00 AMArisan Therapeutics (co-PIs Michael Plewe and Ken McCormack) received a two year Advanced Technology Phase I SBIR award (R43AI12097) in the first quarter of 2014.
Read more -
CalAsia Pharmaceuticals Receives $600,000 SBIR Grant
Posted on News From Our Members by Danielle Hayes · April 10, 2014 9:00 AMCalAsia Pharmaceuticals, founded by SDEE member Sridhar Prasad was awarded a $600,000 NIH Phase I SBIR grant to develop novel antiviral agents for the treatment of Dengue (DENV) fever and West Nile Virus (WNV) infection.
Read more